Aspen Group Stock

Aspen Group ROCE

The Return on Capital Employed (ROCE) of Aspen Group (APZ.AX) as of Aug 5, 2026 is 6.60 %. In the previous year, Return on Capital Employed (ROCE) was 6.03 % — a change of 9.36% (higher).

ROCE

6.60 %

YoY

9.36%

Last updated:

In 2026, Aspen Group's return on capital employed (ROCE) was 6.60 %, a 9.36% increase from the 6.03 % ROCE in the previous year.

Access this data via the Eulerpool API

Aspen Group Stock analysis

What does Aspen Group do? Aspen Group Ltd is a globally active pharmaceutical company headquartered in Durban, South Africa. The company's history dates back to 1850, when the first pharmacy was opened by a man named William Charles in Durban. In 1997, Aspen Group Ltd was founded, which continued William Charles' business and expanded strongly in the following years. Aspen's business model is based on the acquisition of pharmaceutical companies and their products, as well as the production of generics and branded drugs. The company operates worldwide and has offices in over 50 countries. Aspen specializes in the fields of thrombosis, anesthesia, oncology, infectious diseases, and nervous system disorders. The various divisions of Aspen include Aspen Global Commercial, Aspen Pharmacare, Aspen Nutritionals, Aspen Oss, Aspen Business Europe, and Aspen Healthcare. Aspen Global Commercial is responsible for the sale of products in various regions of the world. Aspen Pharmacare is engaged in the production and sale of generics and branded drugs. Aspen Nutritionals produces dietary supplements and baby food. Aspen Oss manufactures and distributes bone substitute materials. Aspen Business Europe is responsible for product distribution in Europe, and Aspen Healthcare operates hospitals and health centers in South Africa. Aspen offers a variety of products, including anticoagulants, anesthetics, antibiotics, cancer drugs, HIV/AIDS medications, as well as dietary supplements and baby food. In the field of thrombosis, the company offers a wide range of anticoagulants, such as the active ingredients heparin, enoxaparin, and fondaparinux. In the field of oncology, Aspen produces drugs for the treatment of breast cancer, colon cancer, and lung cancer. Aspen's products are utilized by many different customers worldwide, including government agencies, hospitals, pharmacies, and retailers. Aspen places great emphasis on the quality of its products and has implemented a quality management system to ensure that the products meet the highest standards. In recent years, there have been controversies surrounding Aspen, particularly regarding drug pricing. In 2016, Aspen was fined €5.2 million by the European Commission for charging unreasonably high prices for cancer drugs in five European countries. Aspen has denied the allegations and announced plans to appeal the decision. Despite these controversies, Aspen remains an important player in the global pharmaceutical market. The company has a wide range of products and operates in various regions of the world. Aspen is committed to improving the health and well-being of people and continuously works to develop innovative and effective medications. Aspen Group is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Aspen Group's Return on Capital Employed (ROCE)

Aspen Group's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Aspen Group's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Aspen Group's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Aspen Group’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Aspen Group stock

Return on Capital Employed (ROCE) of Aspen Group is 6.60 % in 2026.

Return on Capital Employed (ROCE) of Aspen Group changed from 6.03 % to 6.60 %, representing a 9.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Aspen Group since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Aspen Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Aspen Group

All Key Metrics — Aspen Group